Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration Between 2012 and 2022.

Kamat, Samir; Ungar, Benjamin; Agarwal, Aneesh; Wan, Joy; Ross, Joseph S; Gupta, Ravi

Kamat, Samir; Ungar, Benjamin; Agarwal, Aneesh; Wan, Joy; Ross, Joseph S; Gupta, Ravi.

Afiliação

Kamat S; Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, New York.
Ungar B; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Agarwal A; Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, New York.
Wan J; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Ross JS; Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Gupta R; Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.

JAMA Dermatol ; 160(2): 226-229, 2024 Feb 01.

Article em En | MEDLINE | ID: mdl-38117528

This cross-sectional study characterizes the frequency and degree of innovation of new dermatologic drugs approved by the US Food and Drug Administration (FDA) from 2012 to 2022.

Assuntos

Aprovação de Drogas; Estados Unidos; Humanos; United States Food and Drug Administration; Fatores de Tempo

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aprovação de Drogas Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: JAMA Dermatol Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google